title: VEGF Trapon inhibits tumor growth in papillary thyroid carcinoma.
abstract: OBJECTIVE
  Vascular endothelial growth factor (VEGF) is the most potent inducer of neovasculature, and its increased expression has been related to a worse clinical outcome in many disease. Angiogenesis from thyroid cancer cell plays the important roles in post-surgical persistent, recurrent, and metastatic papillary thyroid cancer (PTC). Vascular endothelial growth factor (VEGF) Trapon is a newly developed VEGF-blocking agent with stronger affinity and broader activity than the anti-VEGF antibody bevacizumab. In this study, we tested the activity of VEGF Trapon on a PTC model in vivo.
  
  
  METHODS
  BC-PAP (derived from papillary carcinomas) transfected with a luciferase-expressing vector were injected into the back to mice. I.p. treatment with VEGF Trapon or control protein (25 mg/kg twice weekly) was started shortly after tumor injection to prevent tumor development (prevention model) or after established tumors were formed to inhibit tumor growth and metastasis formation (intervention model).
  
  
  RESULTS
  In the prevention model, VEGF Trapon inhibited tumor growth by 73 ± 12% compared with control (p = 0.014) and significantly prolonged survival. In the intervention model, VEGF Trapon inhibited tumor growth by 68 ± 7% (p < 0.01). Microvascular density was reduced by 56% due to VEGF Trapon treatment (p < 0.01).
  
  
  CONCLUSIONS
  VEGF Trapon is a potent inhibitor of BC-PAP tumor growth, angiogenesis and blocks the biological function of VEGF in vivo. These results support further clinical development of VEGF Trapon for PTC and other cancer types.
authors: Emergency Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China. qyfynm@126.com.
authors: X-G
authors: XG
authors: Peng
authors: Z-F
authors: ZF
authors: Chen
authors: K-J
authors: KJ
authors: Zhang
authors: P-G
authors: PG
authors: Wang
authors: Z-M
authors: ZM
authors: Liu
authors: Z-J
authors: ZJ
authors: Chen
authors: G-Y
authors: GY
authors: Hou
authors: M
authors: M
authors: Niu
mesh_terms: D020533:Angiogenesis Inhibitors; D000818:Animals; D002277:Carcinoma / Q000098:blood supply / Q000188:drug therapy*; D002291:Carcinoma, Papillary / Q000098:blood supply / Q000188:drug therapy*; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C000600282:VEGF Trapon; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A